间充质干细胞在系统性硬化的应用前景

Mesenchymal Stem Cells in the Therapy of Systemic Sclerosis:A New Insight

间充质干细胞(mesenchymal stem cells,MSCs)多存在于骨髓中,是一类具有多向分化能力及免疫调节作用的细胞。近年来,MSCs在自身免疫性疾病中的应用受到很大关注。研究表明,MSCs分化为血管内皮细胞的能力受损在系统性硬化(systemic sclerosis,SSc)的病理改变中起重要作用。同时,另有研究表明,SSc患者的骨髓MSCs与正常人的骨髓MSCs在许多生物学特性上并无差异。MSCs还具有支持造血细胞和免疫抑制的作用,这也可以使之在SSc的自体造血干细胞移植(hematopoietic stem cell transplantation,HSCT)治疗中起到辅助作用。这些研究结果均支持MSCs被应用到SSc的治疗中。本文对MSCs在SSc的应用前景作一综述。

Mesenchymal stem cells（MSCs） mainly stay in the bone marrow and are capable of differentiating along many kind of tissues.These years,there were many researches on the using of MSCs in autoimmune diseases.Recently,it was proved that the impairment of endothelial cell differentiation from MSCs is important in the pathogenesis of systemic sclerosis（SSc）.Other researches showed that there is no significant difference in many features between MSCs of SSc patients and healthy donors.Moreover,MSCs can provide support to the haematopoietic stem cells and exhibit immune suppression functions.These may provide an opportunity of MSCs being used in hematopoietic stem cell transplantation（HSCT） therapy of SSc.All of these support that MSCs could be a potential treatment for SSc.